Number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.

AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. For CTCAE v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE.

The on-treatment period is defined from the day of first administration of study treatment up to 30 days after the date of its last administration.

All patients who had received at least one dose of spartalizumab or capmatinib in the Phase Ib part

A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications that occurs within the first 2 cycles of treatment with capmatinib in combination with spartalizumab during the dose escalation part of the study. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher. The duration of one treatment cycle is 21 days.

Patients in Phase Ib who either met the minimum exposure criterion and had sufficient safety evaluations, or had experienced a DLT during Cycles 1 and 2. A patient was considered to have met the minimum exposure criterion if received at least 2 doses of spartalizumab and 28 days of capmatinib during Cycles 1 and 2. Patients who did not experience a DLT during the first 2 cycles were considered to have sufficient safety evaluations if they had been observed for at least 42 days after first dose.

Number of participants with at least one dose reduction of capmatinib and spartalizumab and number of participants with at least one dose interruption of capmatinib and spartalizumab.

No dose modifications (i.e. dose reduction) were allowed for spartalizumab.

All patients who had received at least one dose of spartalizumab or capmatinib in the Phase Ib part

Dose intensity of capmatinib was calculated as actual cumulative dose in milligrams divided by duration of exposure in days.

All patients who had received at least one dose of spartalizumab or capmatinib in the Phase Ib part

Dose intensity of spartalizumab was calculated as actual cumulative dose in milligrams divided by duration of exposure in weeks and then multiplied by 3 weeks (3W).

All patients who had received at least one dose of spartalizumab or capmatinib in the Phase Ib part

Tumor response was based on local investigator assessment as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. ORR per RECIST v1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR).

For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

All patients to whom study treatment was assigned by randomization in the Phase II part

BOR is defined as the best response recorded from the start of the study treatment until disease progression/recurrence, based on local investigator assessment per RECIST v1.1.

For RECIST v1.1, R=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm; SD= Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression).

The number of participants in each response category is reported in the table.

All patients who received at least one dose of study treatment in the Phase Ib part, and all patients to whom study treatment was assigned by randomization in the Phase II part.

BOR is defined as the best response recorded from the start of the study treatment until disease progression/recurrence, based on local investigator assessment per Immune-related Response Criteria (irRC).

For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new measurable lesions, taking as reference the baseline sum of diameters; irPD= At least a 20% increase in the sum of diameters of all measured target lesions including new measurable lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm; irSD= Neither sufficient shrinkage to qualify for irPR or irCR nor an increase in lesions which would qualify for irPD).

All patients who received at least one dose of study treatment in the Phase Ib part, and all patients to whom study treatment was assigned by randomization in the Phase II part.

Tumor response was based on local investigator assessment as per RECIST v1.1. ORR per RECIST v1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR).

For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

All patients who had received at least one dose of spartalizumab or capmatinib capmatinib in the Phase Ib part

Tumor response was based on local investigator assessment as per irRC. ORR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR) or immune related Partial Response (irPR).

For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new measurable lesions, taking as reference the baseline sum of diameters.

All patients who received at least one dose of study treatment in the Phase Ib part, and all patients to whom study treatment was assigned by randomization in the Phase II part.

DOR only applies to patients for whom best overall response is complete response (CR) or partial response (PR) based on local investigator assessment of overall lesion response according to RECIST v1.1. DOR is defined as the time from the date of first documented response (confirmed CR or confirmed PR) to the date of first documented disease progression or death due to any cause. If a patient not had an event, duration was censored at the date of last adequate tumor assessment before the start of a new anticancer therapy, if any.

According to the statistical analysis plan (SAP), summary estimates of DOR using the Kaplan-Meier method were planned to be reported if there were at least 10 patients achieving a confirmed CR or PR in each treatment group/arm.

All participants in Phase Ib and II for whom best overall response is complete response (CR) or partial response (PR) as per RECIST v1.1 based on local investigator assessment.

DOR only applies to patients for whom best overall response is immune-related complete response (irCR) or immune-related partial response (irPR) based on local investigator assessment of overall lesion response according to irRC. DOR is defined as the time from the date of first documented response (confirmed irCR or confirmed irPR) to the date of first documented disease progression or death due to any cause. If a patient not had an event, duration was censored at the date of last adequate tumor assessment before the start of a new anticancer therapy, if any.

According to the statistical analysis plan (SAP), summary estimates of DOR using the Kaplan-Meier method were planned to be reported if there were at least 10 patients achieving a confirmed irCR or irPR in each treatment group/arm.

All participants in Phase Ib and II for whom best overall response is immune-related complete response (irCR) or immune-related partial response (irPR) as per irRC based on local investigator assessment.

TTR is defined as the time from the date of start of treatment to the date of first documented response (CR or PR, which must be confirmed subsequently) for patients who achieved a confirmed CR or PR. Tumor response was based on local investigator assessment per RECIST v1.1.

Patients who did not achieve a confirmed CR or PR were censored at the maximum follow-up time for patients who had a Progression-Free Survival (PFS) event (i.e. either progressed or died due to any cause), or at the date of last adequate tumor assessment before the start of a new anticancer therapy (if any) otherwise.

According to the statistical analysis plan (SAP), summary estimates of TTR using the Kaplan-Meier method were planned to be reported if there were at least 10 patients achieving a confirmed CR or PR in each treatment group/arm.

All patients who received at least one dose of study treatment in the Phase Ib part, and all patients to whom study treatment was assigned by randomization in the Phase II part.

TTR is defined as the time from the date of start of treatment to the date of first documented response (irCR or irPR, which must be confirmed subsequently) for patients who achieved a confirmed irCR or irPR. Tumor response was based on local investigator assessment per irRC.

Patients who did not achieve a confirmed irCR or irPR were censored at the maximum follow-up time for patients who had a Progression-Free Survival (PFS) event (i.e. either progressed or died due to any cause), or at the date of last adequate tumor assessment before the start of a new anticancer therapy (if any) otherwise.

According to the statistical analysis plan (SAP), summary estimates of TTR using the Kaplan-Meier method were planned to be reported if there were at least 10 patients achieving a confirmed irCR or irPR in each treatment group/arm.

All patients who received at least one dose of study treatment in the Phase Ib part, and all patients to whom study treatment was assigned by randomization in the Phase II part.

PFS is defined as the time from the date of start of treatment to the date of the first documented progression per RECIST v1.1 or death due to any cause. If a patient did not experience an event or started a new anticancer therapy, PFS was censored at the date of the last adequate tumor evaluation before the start of a new anticancer therapy, if any. Tumor response was based on local investigator assessment per RECIST v1.1.

PFS was estimated using the Kaplan-Meier Method.

All patients who received at least one dose of study treatment in the Phase Ib part, and all patientss to whom study treatment was assigned by randomization in the Phase II part.

PFS is defined as the time from the date of start of treatment to the date of the first documented and confirmed progression per irRC or death due to any cause. If a patient did not experience an event or started a new anticancer therapy, PFS was censored at the date of the last adequate tumor evaluation before the start of a new anticancer therapy, if any. Tumor response was based on local investigator assessment per irRC.

PFS was estimated using the Kaplan-Meier Method.

All patients who received at least one dose of study treatment in the Phase Ib part, and all patients to whom study treatment was assigned by randomization in the Phase II part.

TTP is defined as the time from the date of start of treatment to the date of the first documented progression per RECIST v1.1 or death due to underlying cancer. If a patient did not experience an event or started a new anticancer therapy, TTP was censored at the date of the last adequate tumor evaluation before the start of a new anticancer therapy, if any. Tumor response was based on local investigator assessment per RECIST v1.1.

TTP was estimated using the Kaplan-Meier Method.

All patients who received at least one dose of study treatment in the Phase Ib part, and all patients to whom study treatment was assigned by randomization in the Phase II part.

TTP is defined as the time from the date of start of treatment to the date of the first documented and confirmed progression per irRC or death due to underlying cancer. If a patient did not experience an event or started a new anticancer therapy, TTP was censored at the date of the last adequate tumor evaluation before the start of a new anticancer therapy, if any. Tumor response was based on local investigator assessment per irRC.

All patients who received at least one dose of study treatment in the Phase Ib part, and all patients to whom study treatment was assigned by randomization in the Phase II part.

OS is defined as the time from date of start of treatment to date of death due to any cause. If a patient was not known to have died, OS time was censored at the date of last contact.

OS was estimated using the Kaplan-Meier Method.

All patients who received at least one dose of study treatment in the Phase Ib part, and all patients to whom study treatment was assigned by randomization in the Phase II part.

Number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.

AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. For CTCAE v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE.

The on-treatment period is defined from the day of first administration of study treatment up to 30 days after the date of its last administration.

All patients to whom study treatment was assigned by randomization in the Phase II part

Number of participants with at least one dose reduction of capmatinib and spartalizumab and number of participants with at least one dose interruption of capmatinib and spartalizumab.

No dose modifications (i.e. dose reduction) were allowed for spartalizumab.

All patients to whom study treatment was assigned by randomization in the Phase II part

Dose intensity of capmatinib was calculated as actual cumulative dose in milligrams divided by duration of exposure in days.

All patients assigned by randomization to capmatinib in combination with spartalizumab in the Phase II part

Dose intensity of spartalizumab was calculated as actual cumulative dose in milligrams divided by duration of exposure in weeks and then multiplied by 3 weeks (3W).

All patients to whom study treatment was assigned by randomization in the Phase II part

Pharmacokinetic (PK) parameters were calculated based on capmatinib plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed plasma concentration following a dose.

All patients in Phase Ib who provided an evaluable capmatinib PK profile on C2D1. Capmatinib PK profile was considered evaluable if all the following conditions were satisfied: patient took the same dose of capmatinib for at least 3 consecutive days prior to sampling, patient had the pre-dose sample collected before next dose administration and at least 9 hours after last dose administration, patient did not vomit within 4 hours after dosing and patient provided at least 1 primary PK parameter.

Pharmacokinetic (PK) parameters were calculated based on capmatinib plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) plasma concentration following a dose. Actual recorded sampling times were considered for the calculations.

All patients in Phase Ib who provided an evaluable capmatinib PK profile on C2D1. Capmatinib PK profile was considered evaluable if all the following conditions were satisfied: patient took the same dose of capmatinib for at least 3 consecutive days prior to sampling, patient had the pre-dose sample collected before next dose administration and at least 9 hours after last dose administration, patient did not vomit within 4 hours after dosing and patient provided at least 1 primary PK parameter.

Pharmacokinetic (PK) parameters were calculated based on capmatinib plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.

All patients in Phase Ib who provided an evaluable capmatinib PK profile on C2D1. Capmatinib PK profile was considered evaluable if all the following conditions were satisfied: patient took the same dose of capmatinib for at least 3 consecutive days prior to sampling, patient had the pre-dose sample collected before next dose administration and at least 9 hours after last dose administration, patient did not vomit within 4 hours after dosing and patient provided at least 1 primary PK parameter.

Capmatinib plasma concentration was assessed in samples taken at pre-dose. Pre-dose samples were collected before the next dose administration.

All patients in Phase II part who provided an evaluable capmatinib concentration at the specified timepoints. Capmatinib concentration was considered evaluable if all the following conditions were satisfied: patient took the same dose of capmatinib for at least 3 consecutive days prior to sampling, patient had the pre-dose sample collected before next dose administration and at least 9 hours after last dose administration, patient did not vomit within 4 hours after the dosing prior to sampling.

Pharmacokinetic (PK) parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed serum concentration following a dose.

All patients in Phase Ib and Phase II who provided an evaluable PK profile of spartalizumab on Cycle 1 and Cycle 3. The spartalizumab PK profile was considered evaluable if all the following conditions were satisfied: patient received the planned treatment with spartalizumab and patient provided at least 1 primary PK parameter.

Pharmacokinetic (PK) parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) serum concentration following a dose. Actual recorded sampling times were considered for the calculations.

All patients in Phase Ib and Phase II who provided an evaluable PK profile of spartalizumab on Cycle 1 Day 1 and Cycle 3 Day 1. The spartalizumab PK profile was considered evaluable if all the following conditions were satisfied: patient received the planned treatment with spartalizumab and patient provided at least 1 primary PK parameter.

Pharmacokinetic (PK) parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.

All patients in Phase Ib and Phase II who provided an evaluable PK profile of spartalizumab on Cycle 1 Day 1 and Cycle 3 Day 1. The spartalizumab PK profile was considered evaluable if all the following conditions were satisfied: patient received the planned treatment with spartalizumab and patient provided at least 1 primary PK parameter.

The expression of CD8 was measured in tumor samples by immunohistochemical methods. This record summarizes the percent marker area for CD8 expression in tumor samples.

All patients who received at least one dose of study treatment in the Phase Ib part and had a valid assessment for the outcome measure, and all patients to whom study treatment was assigned by randomization in the Phase II part and had a valid assessment for the outcome measure.

The expression of programmed cell death-ligand 1 (PD-L1) was measured in tumor samples by immunohistochemical methods. This record summarizes the PD-L1 positivity percentage in tumor samples.

All patients who received at least one dose of study treatment in the Phase Ib part and had a valid assessment for the outcome measure, and all patients to whom study treatment was assigned by randomization in the Phase II part and had a valid assessment for the outcome measure.

On-treatment and post-treatment safety follow-up deaths were collected from first dose of study medication to 150 days after the last dose of study medication.

Post-treatment survival follow-up deaths were collected from day 151 after last dose of study medication to end of study.

All deaths refer to the sum of on-treatment and post-treatment safety follow-up deaths plus post-treatment survival follow-up deaths.

All patients who received at least one dose of study treatment in the Phase Ib part, and all patients to whom study treatment was assigned by randomization in the Phase II part.